ImmunityBio, Inc. IBRX EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s EPS (diluted)?
- ImmunityBio, Inc. (IBRX) reported EPS (diluted) of -$0.62 in Q1 2026.
- How has ImmunityBio, Inc.'s EPS (diluted) changed year-over-year?
- ImmunityBio, Inc.'s EPS (diluted) decreased by 313.3% year-over-year, from -$0.15 to -$0.62.
- What is the long-term trend for ImmunityBio, Inc.'s EPS (diluted)?
- Over 4 years (2021 to 2025), ImmunityBio, Inc.'s EPS (diluted) has grown at a -19.2% compound annual growth rate (CAGR), from -$0.89 to -$0.38.
- What does EPS (diluted) mean?
- The profit per share assuming all convertible securities are turned into common stock.
- How do you interpret EPS (diluted)?
- A lower diluted EPS compared to basic EPS indicates potential dilution for existing shareholders; higher values are generally preferred.
- How does EPS (diluted) compare across companies?
- Essential for evaluating companies with complex capital structures or significant employee stock compensation.